Your browser is no longer supported. Please, upgrade your browser.
AMRN Amarin Corporation plc daily Stock Chart
Amarin Corporation plc
Index- P/E- EPS (ttm)-0.34 Insider Own1.00% Shs Outstand299.87M Perf Week-32.19%
Market Cap4.61B Forward P/E327.23 EPS next Y0.05 Insider Trans0.00% Shs Float141.77M Perf Month-20.27%
Income-97.80M PEG- EPS next Q-0.10 Inst Own43.90% Short Float12.34% Perf Quarter419.59%
Sales205.80M P/S22.41 EPS this Y45.20% Inst Trans14.50% Short Ratio1.08 Perf Half Y380.63%
Book/sh-0.25 P/B- EPS next Y113.50% ROA-53.20% Target Price30.80 Perf Year338.18%
Cash/sh0.27 P/C56.31 EPS next 5Y22.30% ROE152.40% 52W Range2.35 - 23.33 Perf YTD283.54%
Dividend- P/FCF- EPS past 5Y29.10% ROI-154.70% 52W High-33.94% Beta0.65
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin75.50% 52W Low555.96% ATR1.85
Employees241 Current Ratio1.30 Sales Q/Q16.70% Oper. Margin-40.70% RSI (14)39.32 Volatility14.76% 8.90%
OptionableYes Debt/Eq- EPS Q/Q-107.10% Profit Margin-51.10% Rel Volume1.94 Prev Close15.38
ShortableYes LT Debt/Eq- EarningsNov 01 BMO Payout- Avg Volume16.13M Price15.41
Recom2.00 SMA20-26.57% SMA502.69% SMA200152.47% Volume25,816,843 Change0.23%
Nov-14-18Upgrade Citigroup Neutral → Buy
Nov-02-18Downgrade Citigroup Buy → Neutral
Jun-27-17Resumed Cantor Fitzgerald Overweight
Oct-19-16Initiated Citigroup Buy $5
Oct-05-16Initiated Cantor Fitzgerald Buy $6
May-12-16Resumed Jefferies Buy
Mar-12-15Upgrade H.C. Wainwright Neutral → Buy $2.50 → $10
Apr-01-14Reiterated MKM Partners Neutral $1.50 → $2
Feb-24-14Reiterated MKM Partners Neutral $2.50 → $1.75
Jan-16-14Downgrade MKM Partners Buy → Neutral $2.50
Nov-08-13Reiterated MKM Partners Buy $5 → $2.50
Oct-30-13Initiated FBR Capital Mkt Perform $2
Oct-17-13Reiterated MKM Partners Buy $9 → $5
Oct-17-13Downgrade Canaccord Genuity Buy → Hold $10 → $3
Oct-17-13Downgrade Aegis Capital Buy → Hold
Mar-20-13Initiated Chardan Capital Markets Hold $8.50
Dec-10-12Reiterated Aegis Capital Buy $25 → $35
Dec-07-12Reiterated Aegis Capital Buy $25 → $35
Jul-12-11Initiated MKM Partners Buy $23
Apr-25-11Reiterated Wedbush Outperform $12 → $18
Nov-14-18 09:33AM  Wednesdays Vital Data: Macys, Amarin and Starbucks InvestorPlace
08:35AM  3 Stock Charts for Wednesday: Home Depot, PPL and HollyFrontier InvestorPlace
Nov-13-18 04:33PM  Why Halliburton, Tyson Foods, and Amarin Slumped Today Motley Fool -22.40%
03:35PM  Here's Why Amarin Corporation Tumbled 20% Today Motley Fool
02:41PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amarin Corporation - AMRN PR Newswire
09:53AM  Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down Zacks
Nov-12-18 06:03PM  As Amarin stock drops, CEO says investors should 'understand our data better' CNBC -5.84%
12:39PM  Amarin CEO comments on its new medicine's mixed results i... CNBC Videos
10:33AM  Amarin Trades Down After Release Of Late-Stage Vascepa Trial Results Benzinga
10:33AM  Why Amarin Corporation's Stock Is Falling Today Motley Fool
08:47AM  Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock? Zacks
07:00AM  Today's Research Reports on Trending Tickers: Amarin and Nektar Therapeutics ACCESSWIRE
06:30AM  HLS Therapeutics Announces that Amarin's Vascepa ® (icosapent ethyl) Demonstrates 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attack and Stroke in REDUCE-IT, which Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint CNW Group
Nov-11-18 10:32AM  Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint PR Newswire
Nov-10-18 03:00PM  Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event Primary Composite Endpoint GlobeNewswire
03:00PM  Data on Fish-Oil Pill May Justify Amarin's Surging Stock Price Bloomberg
Nov-09-18 04:29PM  Amarin's Heart-Therapy Update Seen Triggering 36% Share Move Bloomberg
Nov-08-18 09:37PM  Edited Transcript of AMRN earnings conference call or presentation 1-Nov-18 11:30am GMT Thomson Reuters StreetEvents
06:00AM  Amarin to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-06-18 06:51PM  Cramer's lightning round: This stock could recover if the Democrats win the House CNBC
09:31AM  Tuesdays Vital Data: Activision, Amarin and Apple InvestorPlace
Nov-05-18 05:45PM  Amarin (AMRN) Gains But Lags Market: What You Should Know Zacks
Nov-04-18 07:02AM  Why Amarin Stock Jumped 28% in October -- and Why a Bigger Move Could Come Soon Motley Fool
Nov-01-18 07:51AM  Amarin (AMRN) Beats Earnings & Misses Revenues in Q3 Zacks +8.69%
05:19AM  Amarin: 3Q Earnings Snapshot Associated Press
05:00AM  Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations GlobeNewswire
Oct-31-18 06:30AM  Fish Oil Companys 590% Boom Turns Investor Focus to Earnings Comments Bloomberg
Oct-29-18 09:56AM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
Oct-26-18 05:45PM  Amarin (AMRN) Gains As Market Dips: What You Should Know Zacks
05:00AM  Amarin Schedules Webcast Discussion of Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association GlobeNewswire
Oct-25-18 06:00AM  Amarin To Report Third Quarter 2018 Results and Host Conference Call On November 1, 2018 GlobeNewswire
Oct-24-18 08:00AM  Today's Research Reports on Trending Tickers: Alkermes and Amarin ACCESSWIRE
Oct-23-18 08:21AM  Why Investors Are Paying a Premium for These 3 Biotech Stocks Motley Fool +8.29%
Oct-22-18 08:00AM  Today's Research Reports on Trending Tickers: Titan Pharmaceuticals and Amarin Corporation ACCESSWIRE
Oct-19-18 05:45PM  Amarin (AMRN) Dips More Than Broader Markets: What You Should Know Zacks
04:15PM  Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in January 2017 GlobeNewswire
08:45AM  Investor Expectations to Drive Momentum within Ultrapar Participacoes S.A, BioSpecifics Technologies, GSV Capital, 58, Mitel Networks, and Amarin Discovering Underlying Factors of Influence GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Endo International and Amarin ACCESSWIRE
06:34AM  Jim Cramer Shares His Thoughts On Amarin, AT&T, McDonald's And More Benzinga
Oct-18-18 02:44PM  Up 314% in One Day ... and Then Another 58%: How to Find the Next Amarin Motley Fool
Oct-16-18 12:08PM  4 Strong Stocks to Buy That Double As Big Takeover Targets InvestorPlace
Oct-15-18 10:30AM  These Biotech and Cannabis Stocks Have Skyrocketing Potential ACCESSWIRE
Oct-12-18 08:15AM  Is Amarin Corporation PLC a Buy? Motley Fool
08:00AM  Today's Research Reports on Trending Tickers: Amarin and Immunomedics ACCESSWIRE
Oct-10-18 05:45PM  Amarin (AMRN) Stock Moves -1.51%: What You Should Know Zacks
Oct-09-18 09:02AM  Why Amarin Stock Skyrocketed 415% in September Motley Fool -6.93%
Oct-05-18 08:00AM  Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Amarin ACCESSWIRE
Oct-04-18 08:00AM  Today's Research Reports on Trending Tickers: Amarin and Novavax ACCESSWIRE +11.48%
07:30AM  Why This Undiscovered Device Stock Could Be Worth 3x ACCESSWIRE
Oct-03-18 04:24PM  Here's Why Amarin Corporation Jumped Again Today Motley Fool +14.04%
12:19PM  3 Stocks to Buy and Hold for Decades Motley Fool
Oct-02-18 10:30AM  Biotech Market is Rolling and These Companies Need to Be on Your Radar ACCESSWIRE
09:06AM  2 Healthcare Stocks That Soared in September: Can They Keep Climbing? Motley Fool
Oct-01-18 10:28AM  5 Best Biotech Stocks to Buy In October Zacks
08:00AM  Today's Research Reports on Trending Tickers: Viking Therapeutics and Amarin ACCESSWIRE
Sep-30-18 03:00PM  How Big Could Amarin's Vascepa Be? Motley Fool
Sep-29-18 08:00AM  From Fish Oil to Miracle Drug: Weekend Edition Bloomberg
Sep-28-18 05:59PM  Largest Insider Trades of the Week +17.64%
04:32PM  Why Bojangles, Lions Gate Entertainment, and Amarin Jumped Today Motley Fool
03:49PM  Why Amarin Is Rallying Over 10% (Again!) on Friday Motley Fool
11:33AM  Healthcare: 2 Hot Biotech Stocks on Our Radar Motley Fool
Sep-27-18 05:46PM  Amarin's Stock Soars as Fish Oil Drug Lowers Heart Risks Zacks
05:19PM  Amarin to Present at the Cantor Global Healthcare Conference GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Amarin and Amicus Therapeutics ACCESSWIRE
Sep-26-18 10:17PM  3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph Motley Fool
02:27PM  Amarin and Square are among the most important stock charts to watch MarketWatch
10:30AM  These Biotech and Cannabis Stocks Are Skyrocketing ACCESSWIRE
08:26AM  Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars Zacks
Sep-25-18 12:43PM  Analyst: Amarin's Vascepa Results Create Unicorn Potential, M&A Opportunity Benzinga
10:00AM  Forget Tilray, These 2 Biotech Stocks Have Far More Upside Motley Fool
09:24AM  Tuesdays Vital Data: General Electric Company, Snap and Amarin InvestorPlace
09:05AM  Amarin Bulls Turn Huge Profits on Significant Data Results
08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Amarin Corporation and AcelRx Pharmaceuticals ACCESSWIRE
Sep-24-18 09:00PM  Is It Time to Ditch Your Fish Oil Pill for This "Miracle" Medicine? Motley Fool +314.72%
08:07PM  Amarin Surges on Fish-Oil Drug Data The Wall Street Journal
04:55PM  The Big Party in Amarin Stock Is Just Getting Started InvestorPlace
04:33PM  Why Barrick Gold, Amarin, and California Resources Jumped Today Motley Fool
03:19PM  Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It
03:15PM  Drug Stocks Rally Midday; Chinese Stocks Take a Hit
02:43PM  Amarin Surges on Fish-Oil Drug Data The Wall Street Journal
02:40PM  Amarin's 475% Surge Leaves Its Holders Flush and Sellers Crushed Bloomberg
12:14PM  [$$] Surprise Heart Data Is Just the Beginning for Amarin The Wall Street Journal
12:06PM  Biotech News: Why Amarin Stock Is Going Gangbusters Today InvestorPlace
10:29AM  Fish-Oil Heart Medicine Is Rarest of Drug Breakthroughs Bloomberg
07:35AM  Amarin's stock rockets nearly 4-fold after positive trial results MarketWatch
07:33AM  Why Amarin Corporation Stock Is Exploding Higher Today Motley Fool
06:53AM  Amarin shares surge nearly 300% after fish oil capsule showed benefits to heart patients in trial CNBC
05:30AM  HLS Therapeutics Announces that Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint CNW Group
04:30AM  REDUCE-IT Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint GlobeNewswire
Sep-16-18 02:22PM  The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-12-18 09:21AM  REDUCE-IT Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association GlobeNewswire
Sep-11-18 11:31AM  What Does Amarin Corporation plcs (NASDAQ:AMRN) Ownership Structure Look Like? Simply Wall St.
Sep-08-18 08:10PM  Will Amarin Reward Patient Investors? Motley Fool
Sep-06-18 03:02PM  A New Deal Moves MannKind Back From the Brink Motley Fool
Sep-05-18 09:23AM  3 Biotech Stocks That Still Have Major Catalysts in September Motley Fool
Sep-03-18 12:42PM  Why Amarin Corporation Skyrocketed 23.9% in August Motley Fool
Sep-02-18 09:41AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings Benzinga
09:10AM  3 Biotech Stocks That Could Soar Next Week Motley Fool
Aug-26-18 11:00AM  Amarins REDUCE-IT Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results GlobeNewswire
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.